Primary cutaneous follicle center lymphoma is a rare disorder. Although there are several treatment options, large clinical trials on the treatment of primary cutaneous follicle center lymphoma are lacking. Optimal treatment of this disease is unclear. We describe a case of primary cutaneous follicle center lymphoma treated with systemic rituximab, and review the literature.
InTRoducTIon
Primary cutaneous lymphoma is an uncommon disease with estimated incidence of 1/100,000. 1 Primary cutaneous follicle center lymphoma (PCFCL) is the most common subtype of primary cutaneous lymphoma. 2 PCFCL occurs primarily in the elderly with a median age of 51 years and male to female incidence ratio of 1.84. 3, 4 Due to the rarity of the disease, large clinical trials on the treatment of PCFCL are lacking. Optimal treatment of the disease is less clear and based on case reports and small case series. In this article, we present a case of PCFCL treated with systemic rituximab, and review the literature. The clinical course is generally favorable with a five year survival rate exceeding 95%. Similarly, in another retrospective study, 64 patients with PCFCL were treated with surgical excision. 7 Complete remission was achieved in 62 patients (96.8%) among which 23 cases relapsed (37.1%). All 64 patients had single and small cutaneous lesions.
Intralesional IFN alpha for the treatment of PCFCL has been reported in 7 cases. Complete remission rate is 100%, with a relapse rate of 28.57 %. 6 Reported treatment of 104 cases with multi-agent chemotherapy has shown a complete remission rate of 84% and a relapse rate of 48%. Most of these patients had disseminated cutaneous lesions.
Treatment was mostly comprised of CHOP or CHOP-like courses. 6 Intralesional use of rituximab has been reported in 12 cases of PCFCL among which 10 cases achieved complete remission (83.33%) and the remaining two had partial remission. Four of 10 patients with complete remission (40%) developed new skin lesions: two in the originally treated site and two at distant skin sites. 6 In a report of 11 patients with follicle center lymphoma treated with rituximab, there was 100% response rate. Complete remission was achieved in 10 patients. Significantly, most of the patients (64%) had multifocal disease. 
